GeoVax Labs (NASDAQ:GOVX) Announces Earnings Results

GeoVax Labs (NASDAQ:GOVX) released its quarterly earnings data on Tuesday. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38, Zacks reports. The company had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same period last year, the company posted ($4.80) EPS.

GeoVax Labs Price Performance

Shares of NASDAQ:GOVX opened at $2.61 on Friday. The stock has a 50 day moving average price of $2.39 and a 200-day moving average price of $2.59. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Noble Financial upped their price target on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, August 19th. EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 23rd. Alliance Global Partners assumed coverage on GeoVax Labs in a report on Monday. They set a “buy” rating and a $15.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a report on Friday. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, GeoVax Labs presently has a consensus rating of “Buy” and an average price target of $13.25.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.